Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech Advance ADC Candidate ARC-02 into Phase 1 Clinical Trials
Taiho Oncology, Inc., together with Taiho Pharmaceutical Co., Ltd. and Araris Biotech AG, has announced a key regulatory milestone in the development of its investigational oncology therapy ARC-02. The U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for ARC-02, effectively clearing the path for the initiation of a first-in-human Phase 1 clinical trial. This study will evaluate the safety, tolerability, and preliminary efficacy of the therapy in patients with non-Hodgkin lymphoma, a diverse group of blood cancers that originate in the lymphatic system.
The completion of the IND review represents a crucial step in the clinical development process, signaling that the FDA has determined the investigational therapy is sufficiently supported by preclinical data to proceed into human testing. With this clearance, Taiho Oncology is now positioned to begin a dose-escalation Phase 1 study designed to identify an appropriate dosing range and assess early signals of clinical activity. Such early-phase trials are essential in oncology drug development, particularly for innovative modalities like antibody-drug conjugates (ADCs), where balancing efficacy and safety is critical.
ARC-02 is an ADC engineered to target CD79b, a protein commonly expressed on the surface of B cells, including malignant B cells involved in many forms of non-Hodgkin lymphoma. By focusing on this specific target, ARC-02 aims to selectively deliver its cytotoxic payload directly to cancer cells while minimizing damage to healthy tissues. The drug utilizes monomethyl auristatin E (MMAE), a potent anti-mitotic agent frequently used in ADC development due to its ability to disrupt cell division and induce cancer cell death.
The therapy is built on Araris Biotech’s proprietary AraLinQ™ platform, a next-generation ADC technology designed to improve the precision and stability of antibody-drug conjugates. One of the longstanding challenges in ADC development has been achieving consistent and site-specific attachment of the cytotoxic payload to the antibody. AraLinQ™ addresses this issue by enabling highly controlled conjugation processes using standard antibodies, resulting in more uniform and stable ADCs. This approach also supports scalable manufacturing, which is critical for advancing therapies from clinical development to commercial production.
The origins of Araris Biotech further underscore the scientific foundation of this program. The company is a spin-off from leading Swiss research institutions, including the Paul Scherrer Institute and ETH Zurich. These institutions are globally recognized for their contributions to advanced scientific research, particularly in fields such as molecular biology, chemistry, and biomedical engineering. By leveraging this academic heritage, Araris has developed a robust platform that is now being translated into clinical applications through its collaboration with Taiho.
Taiho Pharmaceutical’s acquisition of Araris Biotech in March 2025 marked a strategic move to strengthen its position in the rapidly evolving field of biologics and targeted cancer therapies. Historically known for its expertise in small-molecule oncology drugs, Taiho has been actively expanding its capabilities to include biologics and advanced therapeutic modalities. The integration of Araris’ ADC platform into Taiho’s pipeline represents a significant step in this transformation, enabling the company to diversify its approach to cancer treatment and pursue more precise, mechanism-driven therapies.
The initiation of the ARC-02 clinical trial is particularly noteworthy as it represents the first time a therapeutic candidate developed using the AraLinQ™ platform will be tested in humans. This milestone not only advances the development of ARC-02 itself but also serves as a proof of concept for the broader technology platform. Success in this trial could validate AraLinQ™ as a versatile and scalable approach to ADC development, potentially opening the door to a new generation of targeted cancer therapies.
From a clinical perspective, non-Hodgkin lymphoma remains an area of significant unmet need, despite advances in treatment over recent decades. While many patients respond to existing therapies, including chemotherapy, immunotherapy, and earlier-generation ADCs, a substantial proportion experience relapse or refractory disease. New treatment options that offer improved efficacy and reduced toxicity are therefore critically important. By targeting CD79b with a highly specific and stable ADC, ARC-02 has the potential to address some of these unmet needs and improve outcomes for patients.
Commenting on the milestone, Dr. Fabio Benedetti, Global Chief Medical Officer at Taiho Pharmaceutical, emphasized the importance of advancing the company’s first ADC into clinical development. He noted that the initiation of this trial reflects the continued expansion of Taiho’s oncology pipeline and its commitment to delivering innovative therapies to patients with cancer. The data generated from this early-phase study will play a crucial role in guiding the дальнейшее development of ARC-02, as well as informing future applications of the AraLinQ™ platform.
Looking ahead, the ARC-02 program is expected to contribute valuable insights into the safety and therapeutic potential of next-generation ADCs. As the trial progresses, researchers will closely monitor patient responses, adverse events, and pharmacokinetic profiles to determine the optimal path forward. Positive results could pave the way for subsequent clinical phases and, ultimately, regulatory approval.
In summary, the FDA’s clearance of the IND application for ARC-02 marks a pivotal moment for Taiho Oncology and its partners. It reflects the successful integration of cutting-edge ADC technology with a strategic vision for expanding oncology innovation. As the first clinical test of the AraLinQ™ platform, this trial represents both a significant scientific milestone and a promising step toward the development of more targeted and effective treatments for patients with non-Hodgkin lymphoma.
About AraLinQ™
AraLinQTM is Araris’ ADC technology, which enables site-specific payload attachment to a privileged attachment site on a specific amino acid residue (Q295) within the native antibody Fc framework. Preclinical data demonstrate that when a payload is attached to this site using Araris’ proprietary linkers, the antibody maintains nearly identical performance (e.g. pharmacokinetics and effector functions) to the unconjugated, original antibody. Furthermore, the linker-payload is connected to the antibody through a very strong isopeptide bond resulting in exceptional stability. Once entering a cancer cell via antibody-mediated internalization, the linker can be easily broken to release the payload. All three of these properties are key factors to enable efficient payload delivery and maximize ADC efficacy.
AraLinQTM linkers are hydrophilic, rendering them soluble and avoiding their clumping in water-based solutions like blood. In addition, this linker can have unique branching structures that make it possible to create ADCs that carry multiple payloads of different types. AraLinQ™ allows for the generation of ADCs in one step using “off-the-shelf,” antibodies that are native or engineered. The process is fast, cost-efficient and can be easily upscaled without the need for custom antibody synthesis.
About Taiho Oncology, Inc.
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.
For more information, visit https://www.taihooncology.com/, and follow us on LinkedIn and X.
Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd. Araris and AraLinQ are trademarks of Araris Biotech AG.
About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts.
In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en.
About Araris Biotech AG
Araris Biotech AG, a wholly owned subsidiary of Taiho Pharmaceutical Co., Ltd. (“Taiho”), is a leading biotech company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy.
By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance.
Source Link:https://www.businesswire.com/
